Top broker says Medibank shares could return 19% in FY25

This stock is predicted to produce healthy returns in FY25.

| More on:
A man in a wheelchair stretches both arms into the air in success.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Medibank Private Ltd (ASX: MPL) shares could be a candidate to produce solid returns in FY25 and perhaps beyond, according to a leading broker.

The ASX healthcare share has seen its fair share of volatility, as shown on the chart below, as it was smashed by a cyberattack in October 2022 and then recovered from the fallout.

Created with Highcharts 11.4.3Medibank Private Ltd PriceZoom1M3M6MYTD1Y5Y10YALL2 Jul 20222 Jul 2024Zoom ▾Oct '22Jan '23Apr '23Jul '23Oct '23Jan '24Apr '24Jul '24Jan '23Jan '23Jul '23Jul '23Jan '24Jan '24www.fool.com.au

One leading broker spies an opportunity with the leading Australian private health insurer.

The company could deliver returns through both a rising share price and a growing dividend, according to UBS.

Why UBS is excited about Medibank shares

The broker's positive view on the ASX healthcare share is based on the low ongoing claims inflation, which supports margins remaining in the 8% to 9% range.

Medibank experienced claims inflation, meaning average claims per policy unit, of just 2% during the first half of FY24, compared to guidance of 2.6%. UBS noted FY24 guidance has been upgraded to 2.2% to 2.4%.

The broker described the outcome as "positive" and said it demonstrated that the claims base had "several different gears". UBS noted that claims remained below pre-COVID levels in psych, rehab, respiratory and prosthesis, which was funding higher claims inflation in private surgical.

The broker also pointed out that the favourable claims outcome triggered another customer's $215 million 'giveback.

UBS said the resident claims ratio improved by 0.4 percentage points compared to the prior corresponding period, while the private health insurance net margin rose by 0.1 percentage points to 8.1%.

The broker forecasts that the private health insurance margin will remain "higher for longer" at above 8% between FY24 and FY26, which is a positive for Medibank shares.

Some disappointments

One negative for the ASX healthcare share was that its other costs were "disappointing", with cost growth of 10.9%. There were several "unusual" items, including non-resident commissions increasing by more than 40%, resident commissions being fully expensed, business-as-usual cost inflation of around 5%, and IT security and payroll tax costs of $4 million.

FY24 guidance costs of between $610 million to $615 million implied 4% to 6% cost growth in the second half of FY24, and this will be aided by a "small step-up in productivity gains.

UBS also said policy numbers were "disappointing", falling by 1,800 in the November and December period. The broker attributed this to a "more competitive environment recently", requiring "greater retention activity". UBS said the FY24 guidance of 1.2% to 1.5% policy growth appeared to be "optimistic". The broker's estimate is for 0.9% growth.

Price target and dividend

UBS has a price target of $4.20 on Medibank shares, which suggests a possible rise of 14%. The broker projects Medibank could pay an annual dividend per share of 18 cents, which translates into a fully franked dividend yield of 4.9%.

Together, the capital growth and dividend could produce a total return of around 19% over the next year or so.

Should you invest $1,000 in Flight Centre Travel Group Limited right now?

Before you buy Flight Centre Travel Group Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Flight Centre Travel Group Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Healthcare Shares

Up 175% in 12 months: Bell Potter just upgraded this high-flying ASX 200 share

This share has smashed the market in recent times but the gains may not be over.

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Guess which ASX healthcare stock is rocketing 25% on big UK news

Investors are sending this ASX healthcare stock rocketing on Friday. But why?

Read more »

two men shake hands on a deal.
Healthcare Shares

Can you guess which ASX 300 healthcare stock is rocketing 34% on takeover news

This share is rocketing on Friday after accepting a takeover offer.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Earnings Results

Telix share price jumps 13% on FY24 profit surge

This pharma stock has delivered another stunning result. Here's what it reported.

Read more »

Health professional working on his laptop.
Earnings Results

2 ASX 300 healthcare shares making big moves on earnings updates

Let's see what these two shares reported on Thursday.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

2 ASX 200 pharmaceutical shares surging on big US news

Big news is getting investors excited on Wednesday. Let's find out what is happening.

Read more »

Bored man sitting at his desk with his laptop.
Healthcare Shares

The Cochlear share price hit a 52-week low last week, is it time to buy?

Is this an opportunity worth hearing about?

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Earnings Results

Cochlear share price sinks 10% on half-year result disappointment

Let's see why investors are hitting the sell button this morning.

Read more »